Retatrutide 1 mg: What the Phase 2 Arm Found
The Phase 2 paper reported an estimated mean weight change of −8.7% at 48 weeks in the 1 mg retatrutide group, compared with −2.1% in the shared placebo group.
The Phase 2 paper reported an estimated mean weight change of −8.7% at 48 weeks in the 1 mg retatrutide group, compared with −2.1% in the shared placebo group.
The Phase 2 obesity study reported outcomes across 1 mg, 4 mg, 8 mg and 12 mg assigned groups. The Phase 3 TRIUMPH-1 paper describes 4 mg, 9 mg and 12 mg research arms.
Lilly reported an extension of TRIUMPH-1 for 532 participants who had a baseline BMI of at least 35 and completed and tolerated treatment in the main study. Follow-up extended to 104 weeks.
The 28.3% figure is an average reduction for the 12 mg trial arm at 80 weeks under the sponsor-reported efficacy analysis. The corresponding placebo estimate was 2.2%.
TRIUMPH-1 compared retatrutide with placebo over 80 weeks. In the sponsor’s efficacy analysis, the 12 mg arm showed a 28.3% average reduction in body weight, compared with 2.2% with placebo.
At 24 weeks, the Phase 2 paper reported an estimated mean change of −17.5% in the 12 mg group and −1.6% in the placebo group. This time point was specified for the primary weight endpoint.
The randomized Phase 2 trial enrolled 338 adults and compared several retatrutide groups with placebo. At week 48 the 12 mg group had an estimated mean weight change of −24.2%, compared with −2.1% with placebo.
Phase 2 obesity research tested multiple retatrutide groups against placebo and characterized weight change and adverse events. Phase 3 studied larger populations under new protocols.
ClinicalTrials.gov records contain a study identifier, planned outcomes, eligibility rules and sponsor-provided status information. The registration lets readers trace a protocol across news reports and papers.
Readers may encounter GLP-3 as a catalog or search term. The clinical literature names the investigational molecule retatrutide or LY3437943 and identifies its targets as GLP-1, GIP and glucagon receptors.